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Abstract
Background: Survival time is an important clinical trait for many disease studies. Previous works
have shown certain relationship between patients' gene expression profiles and survival time.
However, due to the censoring effects of survival time and the high dimensionality of gene
expression data, effective and unbiased selection of a gene expression signature to predict survival
probabilities requires further study.
Method: We propose a method for an integrated study of survival time and gene expression. This
method can be summarized as a two-step procedure: in the first step, a moderate number of genes
are pre-selected using correlation or liquid association (LA). Imputation and transformation
methods are employed for the correlation/LA calculation. In the second step, the dimension of the
predictors is further reduced using the modified sliced inverse regression for censored data
(censorSIR).
Results: The new method is tested via both simulated and real data. For the real data application,
we employed a set of 295 breast cancer patients and found a linear combination of 22 gene
expression profiles that are significantly correlated with patients' survival rate.
Conclusion: By an appropriate combination of feature selection and dimension reduction, we find
a method of identifying gene expression signatures which is effective for survival prediction.
Background
The DNA microarray technique allows researchers to
simultaneously interrogate the expression levels of all
genes in an organism. It has been widely applied in dis-
ease studies, such as cancer subtype discovery, cancer/nor-
mal sample discrimination, disease gene identification [1-
3]. Recently several studies have focused on dissecting the
relation between survival time and gene expression [4-7].
One difficulty of these studies is that the survival times are
often right-censored. For example, at the ends of the stud-
ies, some patients may still be alive. We only know that
their survival times are greater than the last follow-up
time, but not the exact survival times. Thus, treating these
censored survival times as the true life times without
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is that microarray gene expression data are often meas-
ured at the full genome scale with tens of thousands of
gene expression profiles, while the number of patients
under study is relatively small, thereby presenting a diffi-
cult variable selection problem.
Many methods of correlating patient survival with gene
expression are one-step procedures. Individual genes,
gene clusters, or linear combinations of genes are selected
by unsupervised or supervised methods. The selected gene
expression signatures are then directly used to predict sur-
vival probabilities. Unsupervised approaches, such as
selecting a small number gene clusters by unsupervised
clustering [8], has the disadvantage that survival pheno-
type information is completely ignored in the feature
selection step. Most currently available methods are
supervised methods. Nguyen et al. [9] proposed to use the
standard partial least square (PLS) method in selecting
linear combinations of genes. The survival phenotype is
utilized because the PLS method selects linear combina-
tions of genes by maximizing their covariances with the
survival time. However, the censoring information has
been ignored in this procedure. Li et al. [4] proposed to
select linear combinations of genes by a partial Cox regres-
sion (PCR) method, which is an extension of PLS method
for censoring data. The results of PLS and PCR are linear
combinations of thousands of genes, which may be diffi-
cult to interpret. Furthermore, the appropriateness of the
proportional hazard assumption underlying the Cox
regression methodology is not free of challenge. A Baye-
sian variable selection approach based on the accelerated
failure time (AFT) model was introduced by Sha et al. [6],
but the performance of this method when the AFT
assumption itself is violated has not yet been extensively
studied.
Recently, several two-step procedure has been introduced.
The first step is the preliminary gene filtering, and the sec-
ond step is to model the survival time with the pre-
selected genes. Li et al. [5] used principal component anal-
ysis (PCA) for pre-selection. In the PCA step, linear com-
binations of genes (called the principal components, PC)
are sequentially identified by maximizing the variances
explained by the PCs, and a small number of PCs that
explain most variances are selected. The second step is to
apply SIR to identify some linear combinations of PCs to
further reduce the dimensionality. This two-step proce-
dure overcomes the difficulty of handling thousands of
genes simultaneously and has a good prediction perform-
ance for patients' survival probabilities. However, its per-
formance and interpretability could be improved. First,
although PCA can effectively reduce the dimension, it
ignores the survival phenotype information. In addition,
with principal components selected in the first step, the
final results are linear combinations of linear combina-
tions of gene expression profiles, of which the meanings
are difficult to interpret. Secondly, although Li et al. [5]
used SIR to identify the joint space of life time and censor
time, they did not conduct the recovery of the life time
space, which should be of the primary interest (see [10]
for more details about the distinction between life time
space and censor time space). Ma et al. [7] proposed a
Lasso (least absolute shrinkage and selection operator, see
[11]) type of approach for simultaneous gene selection
and parameter estimation based on an additive risk
model. In their method, a pre-selection step is used to
select gene expression profiles correlated with survival
time among those patients without censoring. However,
in many real data, censoring rate is often very high. For
example, in the real data we study in this paper, more than
70% of the survival times are censored. Therefore ignoring
the censored patients in pre-selection step may limit the
power of this method.
In this paper, we propose a different two-step procedure
to identify a gene signature to predict patients' survival
probabilities. In the first step, we use a nonparametric
approach to impute the survival probabilities for the cen-
sored patients based on the well-known Kaplan Meier
estimate. We then use the imputed survival probabilities
together with the uncensored survival probabilities to pre-
select genes via either the correlation or the liquid associ-
ation (LA) method [12]. In the second step, we apply the
modified SIR for censored data (censorSIR, [10]) to fur-
ther reduce the dimensionality of the selected genes. Cen-
sorSIR found projection directions in life time space
without imposing any assumption of the structure model
(such as the proportion hazard or AFT) between survival
time and gene expression profiles. We can use these pro-
jection directions to predict survival probabilities or clas-
sify newly diagnosed cancer patients.
The rest of this paper is organized as follows. The method
section will be arranged into two parts: preliminary gene
screening and dimension reduction – censorSIR. Both
simulated and real data will be analyzed to illustrate and
evaluate our method in the result section. A discussion
section is provided at the end.
Method
Preliminary Gene Filtering
For effective use of the current SIR methodology, the
number of genes (G) need to be much smaller than the
number of samples (N). It is not even appropriate to allow
G to be in the same magnitude as N. However, for most
microarray data, G is much larger than N. We therefore
need to first conduct gene screening to reduce the number
of genes. In order to achieve this end, we employ both liq-
uid association (LA) [12,13] and correlation to select can-Page 2 of 11
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building point of view, we prefer to start from a smaller
gene set as long as a reasonable power of prediction can
be obtained. Nevertheless, as pointed out by an anony-
mous referee, in radiation or carcinogen experiments
where tissues are exposed, broad and more global changes
of gene expressions are expected across the genome.
Therefore, if the sample size is small, our preliminary gene
filtering may miss some important genes.
Imputation of Survival Probabilities
Both LA and correlation computation cannot be applied
directly to survival data due to the presence of censoring.
To temper the influence of censoring bias, we propose to
apply the following nonparametric imputation method
for correcting the right-censored survival time before LA/
correlation computation. Let Ti, i ∈ {1,...,N} be the sur-
vival time for patient i and δi be the censoring indicator
such that δi = 0 indicates censoring and 1 indicates actual
death. The imputation procedure can be summarized as:
1. Calculate  the Kaplan-Meier estimate of the survival
probability [14]. Specifically,  where nj
is the number of individuals at-risk just prior to time tj,
and dj is the number of deaths at time tj;
2. Impute the survival probability by the predicted condi-
tional median
3. Calculate the percentile ;
4. Perform the normal quantile transformation on pi.
The normal quantile transformation is necessary for the
LA calculation (see next section) and make our procedure
robust against outliers. Specifically, it is carried out as fol-
lows. For any variable Z observed in the N patients, we
rank all Zi, i = 1,...,N and denote the rank as Ri. The nor-
mally transformed profile is then defined as Φ-1 (Ri/(N +
1)), where Φ(.) is the cumulative standard normal distri-
bution. Notice that, instead of imputing the survival time,
we actually impute the survival probability.
A justification for the above imputation procedure is
given next. Suppose that Z is the true survival time and its
density and survival functions are f(z) and S(z) ≡ P(Z > z),
respectively. If the squared error loss is used, to predict/
impute the true survival time Z for a censored patient with
censoring time Ti(δi = 0), we can compute the conditional
mean given Z > Ti
A natural estimate of S(z) is to use the Kaplan-Meier esti-
mate of the survival function. However, the resulting esti-
mator is inappropriate if the last observation is censored,
because the Kaplan-Meier estimator is undefined beyond
the largest uncensored survival time and the integral will
be infinite [15]. In practice, for many real data, including
the ones we will analyze in this paper, the last observation
is censored. Therefore, we will not adopt this conditional
mean estimate.
If the absolute value of error is used, we can predict the
true survival time Z for a censored observation by the con-
ditional median . This means
which leads to
Now we can estimate the survival probability of  by
, where  is the Kaplan-Meier estimate of sur-
vival function.
It is worth to emphasize that the imputed survival proba-
bilities are only used in the preliminary gene filtering step.
The observed survival time with censoring information
are used in the dimension reduction step by censorSIR.
Liquid Association
LA was originally introduced for studying coexpression
patterns between three genes. Specifically, we assume that
the correlation of two genes (X and Y) may vary, depend-
ing on the underlying cellular states. For example, X and Y
may be positively correlated at state 1, and negatively cor-
related at state 2. The overall correlation coefficient could
be around zero because the positive and negative correla-
tions might cancel each other out. If the expression of
another gene, denoted as Z, can reflect the change of cel-
lular state, the correlation between X and Y can be
detected by conditioning on Z. Suppose that when Z is
lowly expressed, X and Y are positively correlated and
when Z is highly expressed, X and Y are negatively corre-
lated. In other words, the increase in the expression of Z is
associated with the decrease of the correlation between X
and Y . Then the pair (X, Y) is called a negative LA pair
(LAP) of Z and a negative score is assigned. Similarly, if
Sˆi
Sˆi t t
n j d j
n jj i
=
−
≤∏
S S
S
i
i i
i i
=
=
=
⎧
⎨⎪
⎩⎪
ˆ
ˆ /
;
if 
if 
δ
δ
1
2 0
p Si i= −1 
E Z Z T
zf z dzz Ti
S Ti
T
S z dzz Ti
S Ti
i i( | )
( )
( )
( )
( )
.> =
>∫
= +
>∫
T Z Z Ti i= >median ( | )
P Z T P Z Ti i( ) / ( ) / ,> > = 1 2
S T S Ti i( ) ( ) / . = 2
Ti
ˆ( ) /S Ti 2 ˆ( )S tPage 3 of 11
(page number not for citation purposes)
BMC Bioinformatics 2008, 9:417 http://www.biomedcentral.com/1471-2105/9/417the increase in the expression of Z is associated with the
increase of the correlation between X and Y, a positive LA
score is assigned. Extreme LA scores, either positive or neg-
ative, are of interest. In this context of survival studies, we
take the survival probability (after imputation for cen-
sored cases) as the third variable to find gene pairs whose
coexpression pattern may vary as the survival probability
changes. Biologically we expect these genes detected may
be associated with molecular pathways related to survival.
Therefore we wish to select genes with highest LA scores as
candidates for constructing gene signatures to predict sur-
vival phenotype.
Based on [12], the LA of X and Y with respect to Z, which
measures how the conditional expectation of XY given Z
= z varies as z varies, is given by
LA(X, Y|Z) = Eg'(Z),
where
g(z) = E(XY|Z = z).
If Z follows standard normal distribution, the liquid asso-
ciation can be easily computed by Stein's Lemma [16].
where N is the number of samples. Note that due to the
normality assumption of Z, a normal quantile transfor-
mation should be performed before the LA computation
[12]. In this study, we normalize both the survival proba-
bility and gene expression profiles by normal quantile
transformation to ensure the robustness of our method.
Feature selection
After imputation of survival probability and normal
quantile transformation of both survival probability and
gene expression profiles, we can now calculate the corre-
lation between survival probability Z and gene expression
profile X, and the LA score LA(X, Y|Z), where Y is another
gene expression profile. The gene pair (X, Y) is chosen
from the whole genome, therefore we calculate LA scores
for all the G2 gene pairs. Both LA and correlation calcula-
tion can be conducted in the LA website (http://
kiefer.stat2.sinica.edu.tw/LAP3/index.php). The candi-
date genes can be selected from both the correlation and
LA results. Because of the large number of comparisons in
the LA results, the signals may be difficult to detect by
examining each individual LA pair (LAP). One alternative
strategy is to examine a subset of LAPs with the most
extreme LA scores and extract the recurrent patterns of
some genes. We refer those recurrent genes as LA hub
genes. The effectiveness of this strategy is demonstrated in
the Result section.
Dimension Reduction: SIR and Modified SIR for Censored 
Data (censorSIR)
We will briefly introduce SIR and censorSIR in this section
and discuss the related issues of applying censorSIR to
gene expression data. The theoretical derivation and
implementation of censorSIR, as well as a simulation
example are presented in our supplementary materials.
Interested readers are referred to [17] and [10] for more
details. An R package of censorSIR is available at http://
www.bios.unc.edu/~wsun/software.htm.
The original sliced inverse regression (SIR) [17] is a
dimension reduction method for regression problems. It
reduces the dimension of covariates (denoted as X, which
is a matrix with each column corresponding to a single
covariate) by identifying the projection directions β1,...,βk
in the following model
where Y is the response variable, ΣX is the covariance
matrix of X, and the random error  follows an unknown
distribution (we do not need any prior assumption about
the distribution of  in order to estimate β1,...,βk) and is
independent of X. If f is known, then equation (1) is not
much different from a simple neural network model or a
nonlinear regression model. But what makes SIR special is
that β1,...,βk can be estimated while even if f is unknown.
The space spanned by , which is a subspace
spanned by all the columns in X, is called the effective
dimension reduction (e.d.r.) space.
SIR can be implemented as follows. First the response var-
iable Y is sliced into h intervals (SIR is insensitive to the
choice of h as long as h > k). Then the inverse mean E(X|Y)
is estimated by taking the average of all the values of X in
each slice, where X is one predictor, i.e., one column of X.
Finally the projection directions β1,...,βk can be identified
as the eigenvectors in the eigenvalue decomposition of the
between-slice covariance matrix ΣX|Y = Cov[E(X|Y)] with
respect to ΣX = Cov(X) (see [17] for the proof). The
number of significant projections, denoted by k, can be
determined by an asymptotic Chi-square test, which tests
the hypotheses k = m versus k > m for m = 0,...,p - 1, where
p is the number of covariates.
The paper by Li et al. [10] extended the original SIR to cen-
sored data. Denote Y0 as the underlying true survival time,
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observed survival time. Two censoring mechanisms are
discussed:
1. C is independent of X and Y0;
2. Conditional on X, C is independent of Y0.
In the first situation, the general theory of SIR is applica-
ble without modification [10]. However, the second cen-
soring mechanism, which is more common, will
introduce bias to the SIR estimations. To address this
question, Li et al. [10] introduced a two-step procedure.
The basic idea is to estimate a weight function ω(Y, t, X)
for the patient with censoring time Y and covariate X at
time t with t > Y. Specifically, ω(Y, t, X) = S0(t|X)/S0(Y|X),
and S0(t|X) = P(Y0 ≥ t|X). The weight function can be esti-
mated by any kernel method. Effective dimension reduc-
tion (e.d.r.) space of life time can be identified given this
weight function. Because kernel estimation is more effi-
cient in low-dimension spaces, one initial dimension
reduction step is required. Assume that the true underly-
ing survival time Y0 and the censoring time C have dimen-
sion reduction structures given by
and
respectively. First, the uncensored observations and the
censored observations will be sliced separately, namely
the double slicing procedure. Then the joint e.d.r. space of
the underlying survival time and censoring time will be
obtained by taking the eigenvalue decomposition on the
between-slice covariance matrix with respect to the covar-
iance matrix of X. The leading eigenvectors will serve as
the projection directions
After identifying the gene expression signatures (the pro-
jection directions), one can use scatter plots (2d or 3d) or
non-parametric fittings (e.g., splines) to explore the possi-
ble forms of the function g in equation (2). Predictive
model can also be build based on the reduced expression
data. For example, survival models, e.g., Cox proportional
hazard model, can be fitted with the projected directions
as the explanatory variables first and then the fitted model
can be used to predict the survival probability of a newly
diagnosed patient. These gene expression signatures can
also be used to classify the cancer patients into different
treatment groups for better clinical outcomes.
Results and Discussion
Simulation
Clustering is an important feature in gene expression data.
Genes involved in the same or related biological process
are likely to coexpress, so that the expression profiles of
these genes form a cluster. Thus besides simulating inde-
pendent expression profiles, we also simulate gene expres-
sion clusters. Specifically, we simulate four clusters with
the corresponding gene indexes as: (11–15), (16–20), (3,
31–34), (4, 41–44). In each cluster, each vector Xi ∈ Rp of
gene expression is simulated from a multivariate normal
distribution whose marginal distributions are standard
normal, and the five genes are correlated with each other
with a common correlation coefficient ρ. The rest of the
genes are uncorrelated and are simulated by standard nor-
mal distribution. The true survival time is generated by
Y0 = exp (W1β1 + W2β2 + X3β3 + X4β4),
where βk = 0.5 for k = 1,...,4 and
W1 = (0.15X11 + 0.3X12 + 0.45X13 + 0.6X14 + 0.75X15 + 0.5) 
· X1
W2 = (0.15X16 + 0.3X17 + 0.45X18 + 0.6X19 + 0.75X20 + 0.5) 
· X2,
The censoring time is generated by
C = exp (X6γ1 + X7γ2 + X8γ3 + X10γ5),
where γl = 0.1 for l = 1,...,5. The observed survival time is
the minimum of Y0 and C. With n = 500, p = 10, 000, we
generate 50 random samples for ρ = 0.4, and 0.8, repre-
senting the modest and high correlation cases respec-
tively. The censoring rate is about 50% in both cases.
In this setup, the two genes X1 and X2 act as the LA hub
genes. We analyze the simulated data in two steps. In step
one, survival probabilities are imputed and normalized by
normal quantile transformation and candidate genes are
selected based on the LA and the correlation scores. Genes
that appear at least three times in top 50 positive and neg-
ative LA pairs are selected. The first 10 genes with the high-
est correlations with survival probability in absolute
values are also selected. Table 1 reports the average
number of genes selected from LA (n1) and correlation
(n2), the average number of correct genes Ktrue,1 and Ktrue,2
selected, and the average number of predictors Kcluster,2
found in the clusters 31 – 34 and 41 – 44. We took ρ = 0.4
and 0.8 to represent modest and high co-regulation
within a cluster of genes. The LA hub genes X1 and X2 can
be found by LA every time. Correlation also works well
since the genes in the same clusters of X3 and X4 were also
picked up.
Y g k
0
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selected genes, followed by using the first SIR component
as the gene signature score for survival prediction. To test
the effectiveness of gene signature, we want to test if the
gene signature can separate the patients into high and low
risk groups. We define the cutoff as the median of the gene
signature, i.e.
where X is the matrix of genes selected from step one, and
b is the first SIR direction. A testing data set of 1,000 sub-
jects are generated similarly as the training data, we divide
the 1,000 subjects into higher and lower groups based on
whether the score  is higher or lower than the cutoff and
apply the log rank test. The simulation result shows that
the p-value of the log rank test is smaller than 10-22 in
every simulation run. Table 2 reports the quantiles of the
p-values (in log10 scale).
Table 3 reports the average absolute coefficients in the first
SIR direction for (1) true underlying genes 1 to 4; (2) the
genes in the clusters 31–34 and 41–44; and (3) all the
other genes. The genes X3 and X4 have the highest coef-
fcients since they have high first-order correlations with
the survival time. The coefficients of the LA hub genes X1
and X2 are slightly lower than the coefficients of X3 and X4,
but higher than ones of noise genes. In other words, cen-
sorSIR further identifies the true genes by showing higher
weights in the projection direction.
Application in NKI breast cancer data
In this section, we present the results of analyzing the NKI
breast cancer dataset [18] using our method. The data can
be downloaded from http://microarray-pubs.stan
ford.edu/wound_NKI. Because this data set was initially
generated by the Netherlands Cancer Institute (Neder-
lands Kanker Instituut in Dutch, NKI), it is referred to as
NKI breast cancer data or NKI-295. Seventy-nine out of
the 295 patients died before the study ended, which yields
79 real survival times and a heavy censoring rate of 73.2%.
The expression levels of 24,481 genes were measured for
each of the 295 patients.
Gene Signature Identification
Following the steps described in the Method section, we
first impute survival probabilities and normalize the
imputed survival probabilities and gene expression pro-
files by normal quantile transformation. Assigning the
processed survival time as Z, we apply LA with all the
24,481 genes serving as X and Y to calculate LA score
LA(X, Y|Z). We select 11 genes that appear at least 3 times
in the top 50 (positive) or bottom 50 (negative) LA pairs,
as well as 11 genes of which the absolute value of the cor-
relation coefficient with the processed survival time is big-
ger than 0.3 (Table 4). These cutoffs are determined based
on the results of 1000 permutations. In each permutation,
we permute the survival time and censoring time of the
295 patients simultaneously, and then calculate the LA
scores and correlation scores as for un-permuted data. We
use the number of reoccurrences of one gene in top 50 or
bottom 50 LA pairs to evaluate the importance of that
gene. A threshold of three reoccurrences is used to select
LA hub genes. Our simulation tells how many LA hub
genes can occur by chance alone. It turns out that among
the 1000 permutations, on the average there are only four
LA hub genes present, as compared to the 11 LA hub genes
detected in the real data. To evaluate the significance of
correlation score, we record the highest correlation (abso-
lute value) between the processed survival time and all the
24,481 gene expression profiles. In only 3 out of the 1000
permutations, we observe a correlation score greater than
0.3 (absolute value). The permutation results for both LA
and correlation scores indicate that at least the majority of
the genes selected are significantly related with survival
time after the genome-wise multiple testing correction. It
is possible to select more genes based on the correlation
criterion, but we prefer a parsimonious model to serve the
purpose of prediction and avoid overfitting.
x b= ′X ,
x
Table 1: Average numbers of selected and true predictors found 
in simulation
ρ n1 Ktrue,1 n2 Ktrue,2 Kcluster,2
0.8 3.56 2 10 2 7.22
0.4 2.54 2 10 2 2.6
This table reports the average numbers of genes selected from LA 
(n1) and correlation (n2), the average numbers of correct genes 
selected from LA (Ktrue,1) and correlation (Ktrue,2), and the average 
numbers of predictors Kcluster,2 found in the clusters 31 – 34 and 41 – 
44 for ρ = 0.8 and 0.4. The sample size is (n, p) = (500,10000).
Table 2: Quantiles of the p-values (in log10 scale) of the log rank 
test for testing data
ρ 0% 25% 50% 75% 100%
0.8 -48.6007 -41.2775 -36.3042 -28.5859 -22.0066
0.4 -52.4528 -45.4521 -38.5598 -33.7795 -22.1615
Table 3: Coefficients in the censorSIR projection direction in 
simulation
ρ X1 X2 X3 X4 Cluster Other
0.8 0.2441 0.2299 0.6222 0.5825 0.1321 0.1133
0.4 0.2200 0.2331 0.5347 0.5240 0.0620 0.1591
This table reports the average absolute values of the coefficients for 
genes 1–4, genes in the clusters (31–34) and (41–44), and noise genes 
in censorSIR directions.Page 6 of 11
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Table 4: Twenty-two genes selected by LA and correlations
Official Symbol Official Name Annotation
ABCG1 (3) ATP-binding cassette, sub-family G (WHITE), member 1 ATP binding; cholesterol homeostasis
BIRC5 (-0.31) baculoviral IAP repeat-containing 5 (survivin) Colorectal cancer; apoptosis
C5orf30 (3) chromosome 5 open reading frame 30
CENPA (-0.32) centromere protein A chromosome organization and biogenesis
CTSL2 (-0.33) cathepsin L2 cathepsin L activity; proteolysis
E2F7 (-0.31) E2F transcription factor 7 breast cancer cell growth [30].
ERBB2 (3) v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 member of the epidermal growth factor (EGF) receptor family of 
receptor tyrosine kinases; Amplification and/or overexpression in 
numerous cancers, including breast and ovarian tumors
FAM150B (3) family with sequence similarity 150, member B
H06509 (3) mRNA sequence
HJURP (-0.31) Holliday junction recognition protein up-regulated in lung cancer
KIF20A (-0.30) kinesin family member 20A Collaboration of KIF20A and disc large homologue 5 is likely to 
be involved in pancre atic cancer [31]
KIFC1 (-0.30) kinesin family member C1 mitotic sister chromatid segregation
KRT6B (4) keratin 6B Cell Communication; ectoderm development
LOC284072 (3) hypothetical protein
ORMDL2 (4) ORM1 (S. cerevisiae)-like 2 expressed in normal aorta
PDGFRA (4) platelet-derived growth factor receptor, alpha polypeptide Prostate cancer; cell proliferation
PELI1 (3) pellino homolog 1 (Drosophila) role in interleukin-1-mediated signaling through interaction with 
interleukin-1 receptor-associated kinase 4-IRAK-tumor necrosis 
factor receptor-associated factor 6 complex [32]
PERLD1 (5) per1-like domain containing 1 gastric cancer [33]
PRR11 (-0.32) proline rich 11 interact with E2F1, E2F4
PTTG2 (-0.33) pituitary tumor-transforming 2 chromosome organization and biogenesis
QSOX2 (-0.33) quiescin Q6 sulfhydryl oxidase 2 oxidoreductase activity; cell redox homeostasis
TROAP (-0.32) trophinin associated protein (tastin) cell adhesion
The numbers in the parenthesis are either the number of times the gene appear in top/bottom 50 LA pairs or the correlation coefficient. Only 
genes with negative correlations are selected because positive correlations have smaller absolute value. The highest positive correlation is 0.2875, 
which is ranked as 31st by absolute values.
BMC Bioinformatics 2008, 9:417 http://www.biomedcentral.com/1471-2105/9/417The next step is to perform censorSIR on the 22 selected
genes. First, the double-slicing procedure is used to find
the joint e.d.r. space of the true survival time Y0 and the
censoring time C [see Section 3 in additional file 1 for
more details of the double-slicing outputs]. The χ2 test
shows that the first projection direction is significant (p =
0.000144), and the second direction is mildly significant
(p = 0.066), while the other directions are not significant
(p > 0.30). Therefore, we take the first two eigenvectors as
the projection directions in the joint e.d.r. space and con-
tinue to recover the e.d.r. space of true survival time Y0.
Now with only the first eigenvalue being significant (p =
7.66e-5), we have reduced the survival time space to one
dimension (Figure 1) [see Section 3 in additional file 1 for
details of the censorSIR outputs]. In the following discus-
sion, we only consider the projection of gene expression
data in the first projection direction: We fit a
Cox's model with the covariate  such that
The estimated coefficient  is -0.93 (p-value = 2.2e-16),
with 95% confidence interval of hazard rate [0.313,
0.496]. From the coefficients of the 22 genes in the e.d.r.
direction, i.e., β1, we can see that both genes recruited via
correlation and liquid association can have large impacts
on the projection direction (Figure 1). Both positive and
negative coefficients are observed. Since the projection is
positively correlated with survival time, genes with nega-
tive coefficients are possible "oncogenes", meaning higher
expression is associated with higher risk. In contrast, genes
with positive coefficients are possible "tumor repressor
genes", meaning higher expression is associated with
lower risk. We also use Cox's model to test the efficacy of
using each single gene of the 22 genes to predict the sur-
vival probability. The most significant p-value that can be
achieved by a single gene is 4e-11, which is significant, but
much less significant than the result using their linear
combination.
Prediction and Cross-validation
To predict the survival probability of a newly diagnosed
breast cancer patient, we will only need to check the
x = ′β1X
x
h t x h t ax( | ) ( )exp( ) = 0
aˆ
Underlying direction revealed by censorSIRFigure 1
Underlying direction revealed by censorSIR. The first projection direction identified by censor SIR for 22 gene expres-
sion profiles versus survival time. The left panel shows the projection weights on each of the 22 gene expression profiles, i.e., 
the eigenvector corresponding to the biggest eigenvalue. Notice we normalize the eigenvector βi so that  is equal to 1, 
i.e.  The right panel shows the scatter plot between projection direction and survival time.
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BMC Bioinformatics 2008, 9:417 http://www.biomedcentral.com/1471-2105/9/417expression levels of the 22 genes and then compute .
The survival probability of this patient can be easily pre-
dicted using the formula
The baseline hazard function h0(t) can be estimated by the
Breslow estimators after the coefficients of the Cox's
model have been estimated [15,19,20]. Other methods,
including the exact method [21], the discrete method [22]
and the Efron's method [23], can handle observations that
have tied survival times. Most statistical software provides
the baseline cumulative hazard function, for example, the
function "basehaz" in R.
We divide the patients into two groups of approximately
equal sizes (148 vs. 147) based on the gene expression
level ( ). The log-rank test shows that the survival rates of
these two groups are significantly different (p = 2e-13, Fig-
ure 2). Here a note of caution in interpreting the face value
of this significance level is important. As suggested by one
referee, it is instructive to construct a null situation where
the survival data and the gene expression data are com-
pletely unlinked. We took this suggestion by first ran-
domly permuting the gene expression data and then
carrying out the same steps of our gene signature proce-
dure for correlating the permuted gene expression data
with the un-permuted survival data. It turns out that after
the steps of candidate gene selection, the SIR analysis does
not detect any significant direction (p = 0.45) [see Section
3 in additional file 1 for details of the censorSIR outputs].
This is the correct conclusion and if this was the real life
situation, we should stop here. We would not recommend
using the first SIR direction for constructing gene signa-
ture and splitting the patients into high and low risk
groups. However, if one ignored the SIR significance test
and went on to split the patients, then a statistically signif-
icant separation was observed with a significant p-value of
p = 6e-6 [see Section 3 in additional file 1 for a plot of the
results]. This artifact is largely due to the smallness of the
sample size which leads to the chance of overfitting in the
permuted data, a phenomenon similar to the one com-
monly faced in multiple testing without adjustment. This
result speaks for the needs of conducting the SIR signifi-
cance test. In the real data we did find that the first SIR
direction has a significant p-value (p = 7.66e - 05 versus p
= 0.45) and the p-value for the log rank test in comparing
high and low risk groups is also much lower (p = 2e-13 ver-
sus p = 6e-6).
To assess the prediction ability of our method, we carry
out 100 cross-validations. In each cross-validation, we
randomly divide the 295 patients into training and testing
data of sizes 148 and 147, respectively. Only the training
data are used to identify the gene signatures (from survival
time imputation to the censorSIR), and then the identi-
fied gene signature is tested in the testing data. Based on
the training data, genes appear at least three times in the
top/bottom 50 LAPs are selected. The median number of
genes selected via LA is six with 1st/3rd quantiles as four
and eight, respectively. In addition, 10 genes that have the
highest absolute correlation with the processed survival
time are also selected. Five out of 100 cross-validations
have no significant e.d.r. directions (p > 0.05). For the rest
95 cases, we conduct the log-rank test to test how well the
most significant SIR directions differentiate the survival
rates in both training and testing data. For the training
data, the median, 1st, and 3rd quantile of log-rank p-val-
ues are 4.0e-10, 3.2e-11, and 1.0e-8, respectively. For the test-
ing data, the median, 1st, and 3rd quantile of log-rank p-
values are 4.4e-3, 7.2e-4, and 1.4e-2, respectively. Among
the 95 cross-validations, 84 of them yield a testing p-value
smaller than 0.05. We conclude that our method has a
reasonably good prediction power even for such a small
training sample with a high censoring rate.
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The Kaplan-Meier estimates of survival ratesFigure 2
The Kaplan-Meier estimates of survival rates. Survival 
rates are estimated for the two groups of patients of sizes 
148 and 147 based on the expression of the selected gene 
signature. The log-rank test comparing the two curves gives a 
p-value of 2e - 13.
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BMC Bioinformatics 2008, 9:417 http://www.biomedcentral.com/1471-2105/9/417Discussion
In this paper, we have introduced a two-step method for
the joint analysis of survival time and gene expression
data. The first step is the pre-selection of gene expression
profiles. In order to offset the bias of the censored survival
time, we employ a nonparametric method to impute the
censored survival time. This method is simple to imple-
ment but we agree with an anonymous referee that future
improvement would be desirable. Both correlation and
LA are then used as the criteria to pre-select genes related
with the imputed survival time. In the second step, with
these selected genes, the modified SIR for censored data is
conducted to further reduce the dimension of the gene
expression data by identifying a few projection directions.
Two major advantages of censorSIR over other methods
are: 1) it employs the information of both survival time
and gene expressions; 2) it does not require any function
form for the relation between survival time and the pro-
jection directions. No explicit parametric assumptions are
needed in the whole dimension reduction procedure.
A data set of 295 breast cancer patients was analyzed using
the proposed method. A single projection direction (lin-
ear combination of 22 gene expression profiles) was iden-
tified that is significantly related to the survival time.
Several studies have been done on this data set ([18,24-
26]). One gene signature of 70 genes is identified by max-
imizing the accuracy of classifying the patient with distant
metastases within 5 years or not [24]. van de Vijver et al.
[18] showed that this signature of 70 genes can also be
used to predict the survival probabilities of the 295
patients. Chang et al. [25] employed 442 "core serum
response" (CSR) genes for the survival probability predic-
tion. Perou et al. [2,27] have used clustering strategy to
identify a set of 1410 "intrinsic genes", which can be used
to classify patients into five subtypes. Each subtype has
different levels of risk, therefore can be related with sur-
vival time [26]. Although these three gene sets (70-gene,
CSR genes, intrinsic genes) only overlap slightly, they
yield similar prediction strength, which leads to the con-
clusion that overlaps between gene expression signatures
might not be a necessary measure of reproducibility [26].
Majority of the 22 genes we identified have not been
included in these three gene sets. Nevertheless, the high
accuracy of classifying patients in terms of their survival
probabilities by only 22 genes demonstrates the efficacy
of our method.
We have conducted simulation studies to demonstrate the
effectiveness of our method. Our simulation setting
intends to address the dependence issue between gene
profiles. As the results have shown, it is possible that cor-
related genes would be selected as the surrogated genes for
obtaining gene signatures. This is biologically meaningful
because biologically correlated genes are likely to partici-
pate in the same pathways. The LA hub genes represent
higher order interaction structures which would not be
easy to detect by correlation method; see [13] for an illus-
tration in multiple sclerosis candidate gene finding.
One subtle question is how to choose the cutoffs of corre-
lation and liquid association in the pre-selection step.
This would surely depend on the size of dataset. The per-
mutation test of correlations/LA scores as developed
before can be applied. On the other hand, because SIR
requires the inverting of the covariance matrix. Although
there are many on-going studies to sidestep this difficul-
ties (for example [28,29]), like most model or variable
section procedures, their validity should be taken with
caution because some user-specified tuning parameters
are always hidden. Our preference is to preset a relatively
smaller number of genes (so as to assure the stability of
covariance estimation) to begin with. This can be coupled
with the procedure of cross-validation to circumvent the
overfitting problem to some extent. On the other hand,
biological network affecting the survival phenotype is
complex and is likely to involve multiple pathways. Thus
practically it is unlikely for any method to claim the abil-
ity of identifying all genes involved in the survival net-
work. An effective gene signature can still be obtained
without having to find every single gene in generating the
survival time.
Conclusion
In summary, we propose an effective dimension reduction
and variable selection method to dissect the relationship
between gene expression profiles and survival times.
Compared with most available methods, our method has
two major advantages. Firstly, not only the correlation but
also the dynamic correlation between gene expression and
survival time are explored by employing liquid associa-
tion (LA) as part of the feature selection criteria; Secondly,
no model assumption is required on the relationship
between gene expression and survival time.
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